Congratulations to Our Digital RESI September Innovation Challenge Winners!

17 Sep

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day Digital Redefining Early Stage Investments (RESI) September Conference came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. Each participating finalist company had a dedicated page featuring a virtual poster, short pitch, and other supplementary materials available for viewing.

The Digital RESI September Live Agenda is open to registered attendees until October 14, so there’s still time to check out the Digital RESI September Live Agenda for virtual exhibit of innovative technologies across all life science & healthcare sectors!

The RESI Team would like to thank every Innovation Challenge company for their virtual presentations, and the hard work to promote their technologies to our RESI community. The Top 3 winners will be awarded with free tickets to future RESI conferences. Congratulations to the Top 3 winners, and thanks to all for voting!

First Place: SentiAR

SentiAR (St. Louis, MO) is developing the first application of Mixed Reality technology for use during cardiac ablation procedures, including the treatment of atrial fibrillation. The SentiAR platform provides an immersive command-center for the clinicians by presenting a 3D hologram of the patient’s electroanatomic data via the Microsoft HoloLens in real-time. Our solution gives the clinician unprecedented control via SentiAR’s patent protected, intuitive gaze interface and provides invaluable insight to guide physician diagnosis and catheter placement.

 

Second Place: InvivoSciences

Madison, WI based InvivoSciences (IVS) is a pre-clinical-stage biotech company developing heart failure (HF) therapeutics using a precision medicine approach to extend lifespan of patients.  Our mission is to cure heart failure one gene at a time. It is driven by the urgency of heart failure patients who need more effective and safe therapies.

Our Breakthrough platform discovery technology rapidly analyzes safety and efficacy profile of a given treatment for specific patient group cost-effectively before expensive trials. IVS matchmakes the best treatment for the patient group and expedites the early discovery, clinical trials, and post-product launch monitoring, bringing tremendous value before investing significant resources in human trials.

We have leveraged our breakthrough precision medicine discovery platform using patient-derived human micro heart on a chip Nuheart TM to identify and validate multiple drug pipelines rapidly.

Collaborative patient-driven precision medicine-based drug development empowered with our novel platform can lead to meaningfully better outcomes for heart failure patients, which we refer as InvivoSciences’ discovery engine to develop target therapies. To help move our programs forward InvivoSciences is seeking world class life science investors and strategic partners.

 

Third Place: Cybrexa Therapeutics 

Cybrexa Therapeutics is a private oncology-focused biotech developing a new class of therapeutics based on our alphalex™ platform.

The company anticipates its lead program, CBX-12 (alphalex™-exatecan), will enter Phase I/II in early 2021.  CBX-12 is an alphalex™ conjugate that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 was selected based on its strong efficacy and solid  safety profile demonstrated to date in preclinical studies. CBX-12 has potential synergy with PD-1 inhibitors and other immuno-oncology drugs. Cybrexa plans to publish preclinical data for CBX-12 in the first half of 2020 and to advance the program into the clinic in 2021, with clinical efficacy and safety data expected by 2022.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: